CD3G and neoplasm: Expanding on this, CARs incorporating signaling domains from CD3δ or CD3γ in the context of the 41BB co-stimulatory domain show enhanced anti-tumor efficacy, reduced tonic signaling, and lower cytokine secretion compared to BBζ CARs (3).